Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug survey for rare kidney disease: is fabhalta the answer?

NCT ID NCT07156149

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 18 times

Summary

This study is tracking 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it controls the disease in everyday medical practice. The study will monitor infections, side effects, and kidney function over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 466-8650, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    RECRUITING

    Hirosaki, Aomori, 036 8563, Japan

  • Novartis Investigative Site

    RECRUITING

    Chiba, Chiba, 2608677, Japan

  • Novartis Investigative Site

    RECRUITING

    Kitakyushu, Fukuoka, 8028555, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 0040041, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060-8604, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Tsukuba, Ibaraki, 3058576, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Komatsu, Ishikawa-ken, 923-0961, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Shimajiri-Gun, Okinawa, 901-1303, Japan

  • Novartis Investigative Site

    RECRUITING

    Suita, Osaka, 565-0871, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Takatsuki, Osaka, 5698686, Japan

  • Novartis Investigative Site

    RECRUITING

    Kusatsu, Shiga, 525-8585, Japan

  • Novartis Investigative Site

    RECRUITING

    Ohtsu, Shiga, 5202192, Japan

  • Novartis Investigative Site

    RECRUITING

    Shimotsuga Gun, Tochigi, 321-0293, Japan

  • Novartis Investigative Site

    RECRUITING

    Tokushima, Tokushima, 7708503, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Bunkyo-ku, Tokyo, 1138519, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 1838561, Japan

  • Novartis Investigative Site

    RECRUITING

    Nakano City, Tokyo, 164-8607, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Yosa, Yosa, 629-2261, Japan

  • Novartis Investigative Site

    RECRUITING

    Hiroshima, 734 8530, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Nara, 630-8581, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Wakayama, 640-8558, Japan

Conditions

Explore the condition pages connected to this study.

C3 GLOMERULOPATHY C3 GLOMERULOPATHY